Objectives: This study examined pre-adolescent use of harmful but legally obtainable products (HLPs) "in order to get high" in 4 communities in northwest and southeast Alaska. These products include inhalants, over-the-counter medications, prescription medications taken without a doctor's prescription and common household products.
Study Design: Cross-sectional survey.
Methods: A student survey was administered to the 447 students whose parents consented and who agreed to participate. A descriptive analysis with frequencies, percentages, bivariate associations and appropriate statistical tests produced the study results.
Results: The lifetime overall use of HLPs among fifth, sixth and seventh grade students in 4 Alaskan communities was 17.4%. The lifetime use of inhalants (6.8%) and prescription medications taken without a doctor's prescription (8.0%) appear to be comparable to use rates from other studies. The use of over-the-counter medications (5.7%) appears to be slightly higher than in other U.S. surveys. The use of common household products was 6.1%. No significant differences in the lifetime or 30-day use were found correlated to region, gender, ethnicity or student grade. There was a strong association between 30-day or lifetime use of some HLPs and the (30-day or lifetime) use of alcohol, cigarettes and smokeless tobacco.
Conclusions: The use of harmful everyday legal products by fifth, sixth and seventh graders in Alaska appears to be similar to data collected in other parts of the country. The possibility that there may be a link between the use of available legal substances and alcohol, tobacco and marijuana deserves additional attention.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2443952 | PMC |
http://dx.doi.org/10.3402/ijch.v66i5.18314 | DOI Listing |
Background: A Medicare Voluntary Advance Directive Framework (Framework) would enable the creation, storage, and sharing of advance directive documents, ensuring end-of-life care appropriately honors the individual and their care wishes, while supporting healthcare teams and family members in making care decisions for their patients and loved ones. With Medicare enrollment reaching over 65 million beneficiaries in 2023, and Alzheimer's becoming one of the most expensive conditions - CMS policy makers have a growing responsibility to improve care quality at end-of-life.
Method: The federal government will be called upon to assist providers in navigating documents and legal variations of approved forms of directives among the different states, and in ensuring privacy standards that keep an individual's health data secure.
Alzheimers Dement
December 2024
Center for Life Ethics, University of Bonn, Bonn, Germany.
Background: The possibilities to determine the individual risk of persons to develop future Alzheimer's Disease and dementia have greatly increased in recent years. Promising and little invasive methods, e.g.
View Article and Find Full Text PDFBackground: Estimating the incidence and prevalence of dementia is challenging. Cohort and brain banking studies can provide very precise estimates of incidence and prevalence in specific populations, but it is not clear how generalizable those estimates are to other populations. Furthermore, diagnoses of dementia made in clinical practice may differ from gold-standard neuropathological diagnoses.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Center for Health Disparities Research, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Background: Research is needed to understand the impact of the exposome on ADRD, and development of a secure research infrastructure that facilitates linkage of exposome metrics to biological outcomes is critical. Such linkages are challenging because they often require working with protected health information (PHI) covered under the Health Insurance Portability and Accountability Act (HIPAA). In response, we have developed a robust administrative, legal, and cybersecurity infrastructure at the University of Wisconsin (UW) to establish a novel, PHI-capable, multi-site service for exposome data linkage for the ADRD research community: "Expo-AD".
View Article and Find Full Text PDFCannabis
December 2024
Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton.
Objective: Little is known about the population-level impact of recreational cannabis legalization on trends in opioid-related mortality. Increased access to cannabis due to legalization has been hypothesized to reduce opioid-related deaths because of the potential opioid-sparing effects of cannabis. The objective of this study was to examine the relations between national retail sales of recreational (non-medical) cannabis and opioid overdose deaths in the 5 years following legalization in Canada.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!